ATG16L1 (Autophagy Related 16 Like 1) is a core autophagy protein essential for autophagosome formation and cellular protein quality control. This page provides detailed information about its structure, function, and role in neurodegenerative disease processes.
| Protein Name | Autophagy Related 16 Like 1 |
|---|---|
| Gene | ATG16L1 |
| UniProt ID | Q9Y478 |
| PDB Structures | 4TXW, 4TZY, 5CUX |
| Molecular Weight | 65.9 kDa (607 amino acids) |
| Subcellular Localization | Autophagosome membrane, Cytoplasm |
| Protein Family | ATG16 family |
| Expression | Brain, Liver, Kidney, Heart |
ATG16L1 is a core autophagy protein essential for autophagosome formation. It forms a complex with ATG12-ATG5 that functions as an E3 ligase for LC3/GABARAP lipidation. ATG16L1 is recruited to the phagophore assembly site by ATG14L and mediates the conjugation of LC3 to phosphatidylethanolamine on the expanding autophagosome membrane. ATG16L1 is crucial for both conventional autophagy and selective autophagy pathways including mitophagy, aggrephagy, and xenophagy. It plays essential roles in protein quality control and cellular homeostasis in neurons (Mizushima et al., 2011; Glick et al., 2010).
In the central nervous system, ATG16L1 is expressed in neurons and glial cells throughout the brain, including the cortex, hippocampus, and substantia nigra. Its function in autophagy is critical for maintaining neuronal health, as neurons are long-lived cells that require robust protein quality control mechanisms to prevent the accumulation of damaged proteins and organelles.
ATG16L1 is a 607-amino acid protein with a modular domain architecture:
N-terminal ATG5-binding Domain (residues 1–150): Mediates interaction with ATG5, which is essential for forming the ATG12-ATG5-ATG16L1 complex. This region contains a coiled-coil domain that facilitates protein dimerization.
Coiled-Coil Domain (residues 150–300): Important for homodimerization of ATG16L1. The dimerized form creates a multivalent platform that enhances ATG5 binding.
LC3-interacting Region (LIR, residues 280–320): Enables binding to LC3/GABARAP proteins on autophagosomes, facilitating the recruitment of cargo receptors for selective autophagy.
C-terminal WD40 Repeat Domain (residues 350–607): A beta-propeller structure that mediates protein-protein interactions and may contribute to cargo recognition. This domain is involved in targeting ATG16L1 to specific membrane compartments.
The ATG16L1 protein forms a stable heterotrimeric complex with ATG12-ATG5, which then dimerizes to form a larger complex. This quaternary structure creates multiple binding sites for LC3, enhancing the efficiency of LC3 lipidation.
ATG16L1 plays a central role in autophagy by serving as the E3 ligase component of the LC3 conjugation system:
ATG12-ATG5 Conjugation: ATG16L1 forms a covalent complex with ATG5 through isopeptide bond formation. This conjugation is mediated by ATG7 (E1 enzyme) and ATG10 (E2 enzyme).
Phagophore Recruitment: The ATG12-ATG5-ATG16L1 complex is recruited to the phagophore assembly site (PAS) by ATG14L. Here, it localizes to the expanding phagophore membrane.
LC3 Lipidation: The complex functions as an E3 ligase, facilitating the conjugation of LC3 (and related GABARAP proteins) to phosphatidylethanolamine (PE). This lipidation is essential for autophagosome closure and function.
Autophagosome Maturation: ATG16L1 remains associated with the autophagosome until fusion with lysosomes, contributing to cargo recognition and selective autophagy.
ATG16L1 is involved in multiple selective autophagy pathways:
In neurons, ATG16L1-mediated autophagy is critical for:
ATG16L1 dysfunction may contribute to Alzheimer's disease pathogenesis through impaired autophagy:
In Parkinson's disease, ATG16L1 plays important roles:
ATG16L1 dysfunction may contribute to ALS pathogenesis:
Targeting ATG16L1 and autophagy pathways presents therapeutic opportunities:
ATG16L1 interacts with several key autophagy proteins:
The study of Atg16L1 Protein Autophagy Related 16 Like 1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Page expanded: 2026-03-06